Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial

Manzini et al., BMC Infectious Diseases, doi:10.1186/s12879-022-07716-5, PLACO COVID, NCT04428021
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -25% Improvement Relative Risk Death/intubation -10% Time to viral- -6% Conv. Plasma  PLACO COVID  LATE TREATMENT  DB RCT Is late treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 120 patients in Italy (June 2020 - August 2021) Higher mortality with convalescent plasma (not stat. sig., p=0.54) c19early.org Manzini et al., BMC Infectious Diseases, Nov 2022 Favorsconv. plasma Favorscontrol 0 0.5 1 1.5 2+
RCT 180 hospitalized COVID-19 patients with respiratory impairment in Italy showing no significant improvement in mortality or mechanical ventilation with either standard plasma or COVID-19 convalescent plasma compared to standard of care.
risk of death, 25.0% higher, RR 1.25, p = 0.54, treatment 14 of 60 (23.3%), control 12 of 60 (20.0%), adjusted per study, day 30.
risk of death/intubation, 10.0% higher, RR 1.10, p = 0.76, treatment 17 of 59 (28.8%), control 14 of 56 (25.0%), day 30.
time to viral-, 6.4% higher, relative time 1.06, p = 0.76, treatment 60, control 60, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Manzini et al., 22 Nov 2022, Double Blind Randomized Controlled Trial, Italy, peer-reviewed, median age 66.6, 54 authors, study period June 2020 - August 2021, trial NCT04428021 (history) (PLACO COVID). Contact: pmanzini@cittadellasalute.to.it (corresponding author).
This PaperConv. PlasmaAll
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
Paola Maria Manzini, Giovannino Ciccone, Francesco Giuseppe De Rosa, Rossana Cavallo, Valeria Ghisetti, Sergio D’antico, Claudia Galassi, Fabio Saccona, Anna Castiglione, Nadia Birocco, Tiziana Francisci, Huijing Hu, Clara Pecoraro, Franca Danielle, Luciana Labanca, Anna Maria Bordiga, Marco Lorenzi, Giovanni Camisasca, Osvaldo Giachino, Mauro Pagliarino, Piero Ottone, Ilvana Tiziana Donatella Scuvera, Roberto Guaschino, Roberto Freilone, Pierluigi Berti, Fabrizia Pittaluga, Maria Avolio, Cristina Costa, Samuele Raso, Aurora Nucci, Massimo Milan, Alessandra Baffa, Alessandra Russo, Antonella Tornello, Laura Maddalena, Grazia Delios, Fabio Paolo Marletto, Anna Grazia De Micheli, Alessio Mattei, Stefano Baldassano, Francesca Canta, Maria Luisa Russo, Daniele Bergamo, Francesco Vitale, Marco Maria Liccardi, Alessandra Chinaglia, Andrea Calcagno, Marcella Converso, Chiara Aldieri, Valentina Libanore, Ilaria Blangetti, Valentina Benedetti, Barbara Mitola, Gitana Scozzari, MD Franco Castagno, MD Adriano Valfrè, MSc Gabriella Rizzioli, Teresa D’amato, MSc Cristina Crocillà, MSc Silvana Naselli, MSc Valentino Granero, MSc Grazia Cornagliotto, MSc Graziella Lucania, MSc Cristiana Scaglia, Francesca Ferro, MSc Carmela Solimine, MSc Monica Ricotti, Cristina Gilestro, Remigio Roncato, Angela Palladino, Daniela Ongaro, Giulia Anna Poggio, MD Chiara Chiappero, Simone Mornese Pinna, MD Silvia Scabini, MD Federico Vischia, MD Maria Grazia Gregoretti, MD Enrico Lupia, Prof Luca Brazzi, Prof Carlo Albera, MD Luca Scaglione, MD Valter Gallo, MD Claudio Norbiato, MD Roberto Albiani, MD Bruno Lucio Sini, MD Andrea Fassiola, MD Alessandro Locatelli, Giovanni Di Perri, MD Mauro Navarra, MD Isabella Gardini, MD Aurora Ciardiello, Rita La Grotta, Anna De Rosa, MD Paola Pasquino, MD Gilberto Fiore, MD Orietta Franza, MD Paola Artoni, MD Stefano Meinardi, MD Liliana Calosso, MD Paola Molino, MD Maria Grazia Veglio, MD Tiziana Beltramo, MD Odetta Camerini, MD Karol Giancaspero, MD Franca Napoli, MD Alberto Perboni, MD Emanuela Messa, MD Fabrizio Buffolo, MD Fiammetta Pagnozzi, MD Stefania Bertone, MD Lorenzo Lutri, MD Umberto Gravante, Petros Sacchetti, MD Alessandra Pavan, MD Enzo Castenetto, MD Marco Novelli, MD Marco Tucciarone, MD Patrizia Ocello, MD Giulia Guido, MD Chiara Frascaroli, Daniela Maria Luisa Vivenza, MD Francesca Patti, MD Laura Lorenzelli, MD Guido Balduzzi, MD Deborah Ratti, Laura Mazzucco, Valeria Balbo, MD Francesca Pollis, MD Sabrina Leoncino, MD Chiara Lupo, MD Daniele Romano, MD Silvia Ziccardi, MD Melania Marmifero, MD Guido Chichino, MD Mario Salio, MD Giuseppe Aiosa, MD Riccardo Boverio, MD Ilaria Avonto, MD Sara Ghiotto, MD Riccardo Balbo, MD Vincenza Nico, MD Chiara Aguzzi, Maria Chiara Pellegrino, Maristella Prucca, MSc Lucia Assunta Longa, Laura Perotti, Federica Piovano, MD Luca Ambrogio, MD Marco Formica, MD Elisa Monge, MD Flavia Arena, MD Nicoletta Barzaghi, MD Silvia Tavera, MD Mariaelisa Canepari, MD Guido Strani, MD Fulvio Pomero, MD Maria Grazia Cianci, MD Mariella Gianarda, MD Leonardo Ruscitto, MD Daniel De Martino, MD Sandro Macchi, MD Michele Montagnana, MD Vladimiro Grandinetti, MD Silvia Magnani, MD Elisabetta Radin, MD Valentina Pellu, MD Monica Meucci, MD Erika Noè, MD Paola Torti, MD Luca Montagnani, MD Giulio Doveri, Gabriella Giustetto, Costantino Avdis, Marco Prina, Franco Eliantonio, MD Francesco Lemut, MD Giuseppe Semino, Palmina Spidalieri, MD Domenico Vallino, MD Roberto Prota, MD Gabriella Buono, MD Vincenzo Segala, Maria Grazia Milia, MD Franco Aprà, MD Sergio Livigni, MD Emilpaolo Manno, MD Giuseppe Caula, MD Emanuela Vitali, MD Nicola Liuzzi, MD Mauro Pastorelli, MD Pietro Caironi, MD Federica Gamna, MD Bruno Scapino, MD Lorenzo Gurioli, MD Emanuele Magro, MD Giuseppe Roberti, MD Gian Mario Santamaria, MD Antonella Daffonchio, MD Paola Varese, MD Gianfranco Ghiazza, MD Margherita Girino, Carolina Pelazza, MD Fabrizio Racca, MD Mirco Grillo, Valerio Del Bono, MD Giorgio Gianotto, MD Enzo Aluffi, MD Enrico Ravera
BMC Infectious Diseases, doi:10.1186/s12879-022-07716-5
Background: The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies. Methods: To determine whether convalescent or standard plasma would improve outcomes for adults in early phase of Covid19 respiratory impairment we designed this randomized, three-arms, clinical trial (PLACO COVID) blinded on interventional arms that was conducted from June 2020 to August 2021. It was a multicentric trial at 19 Italian hospitals. We enrolled 180 hospitalized adult patients with COVID-19 pneumonia within 5 days from the onset of respiratory distress. Patients were randomly assigned in a 1:1:1 ratio to standard of care (n = 60) or standard of care + three units of standard plasma (n = 60) or standard of care + three units of high-titre convalescent plasma (n = 60) administered on days 1, 3, 5 after randomization. Primary outcome was 30-days mortality. Secondary outcomes were: incidence of mechanical ventilation or death at day 30, 6-month mortality, proportion of days with mechanical ventilation on total length of hospital stay, IgG anti-SARS-CoV-2 seroconversion, viral clearance from plasma and respiratory
Abbreviations Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s12879-022-07716-5. Additional file 1. Supplementary appendix. Author contributions PMM is the Chief Investigator; she conceived the study, led the proposal and protocol development and wrote the manuscript. GCi, FGDR, CG, SDA, FS, ACas, ML, GCa, OG, AMB, AT, LB, LS, Cav, MPri, FE, contributed to study design and to development of the proposal. GCi was the lead trial methodologist. FS, ACas were trial metodologists and they analyzed results. FD, LL, designed logistic organization for CCP preparation and distribution. TF, HH, CP, MP, PO, ITS, RG, RF, PB, AN, LMa, FPM, SR, AB, AR, MMi, GD, FCas, AV, RR, AP, DO, RA, BLS, IG, ACi, RLG, ADR, LC, TB, OC, KG, FN, MT, PO, GBa, LMaz, VB, MPr, LAL, MGC, MGia, LR, DDM, SMa, MMo, GSe, PSp, GGia organized donors' selection and recruitment and plasma and CCP collection in their hospitals. TF, HH, CP, GD, GGu, CF, DMLV, FPol, SLe, ChL, DRo, SZ, MeMa, IA, SG, RBa, VN, CA, MCP, ST, MCa, GSt, VlG, organized patients' data collection for their centers. BM, GSc, CP were responsible for coordinating Hospital organization for the trial. RC, VG, FD, LL, FP, MA, CC, MGM, organized and performed all donors and patients serological and RT-PCR tests. GC, GL, CSc, FF, CSo, MR, CG, organized plasma and CCP fractionation, treatment and stockage. GR, TDA, CC, SN, VaG, LP, FPio, GGiu, organized CCP and plasma blinding..
References
Abolghasemi, Eshghi, Cheraghali, Fooladi, Moghaddam et al., Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study, Transfus Apher Sci
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Alqahtani, Abdulrahman, Almadani, Alali, Zamrooni et al., Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease, Infect Dis
Arrigo, Hospital, Saints Anthony and Biagio and
Avendaño-Solà, Ramos-Martínez, Muñez-Rubio, Ruiz-Antorán, De Molina et al., Convalescent plasma for COVID-19: a multicenter, randomized clinical trial, Infect Dis
Axfors, Janiaud, Schmitt, Van't Hooft, Smith et al., Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials, BMC Infect Dis
Bajpai, Kumar, Maheshwari, Chhabra, Gupta, Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial, Infect Dis
Balcells, Rojas, Corre, Martínez-Valdebenito, Ceballos et al., Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial, PLoS Med
Bégin, Callum, Jamula, Cook, Heddle et al., Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial, Nat Med, doi:10.1038/s41591-021-01488-2
Chen, Lan, Yuan, Deng, Li et al., Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity, Emerg Microbes Infect
Chen, Zhao, Qu, Chen, Xiong et al., Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019, Clin Infect Dis
Cheng, Wong, Soo, Wong, Lee et al., Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis
Diseases, Croce, Cuneo, District, Cuneo, 27 Infectious Diseases Unit
Duan, Liu, Li, Zhang, Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci
Eberhardt, Meyer-Schwickerath, Heger, Knops, Lehmann et al., RNAemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients, Viruses
Gharbharan, Jordans, Geurtsvankessel, Hollander, Karim et al., Convalescent Plasma for COVID-19. A randomized clinical trial, Infect Dis
Hagman, Hedenstierna, Gille-Johnson, Hammas, Grabbe et al., Severe acute respiratory syndrome coronavirus 2 RNA in serum as predictor of severe outcome in coronavirus disease 2019: a retrospective cohort study, Clin Infect Dis
Hegerova, Gooley, Sweerus, Maree, Bailey et al., Use of convalescent plasma in hospitalized patients with COVID-19: case series, Blood
Hogan, Stevens, Sahoo, Huang, Garamani et al., High frequency of SARS-CoV-2 RNAemia and association with severe disease, Clin Infect Dis
Hung, To, Lee, Lee, Yan, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis
Joyner, Bruno, Klassen, Kunze, Johnson et al., Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin Proc
Joyner, Carter, Senefeld, Klassen, Mills et al., Convalescent plasma antibody levels and the risk of death from COVID-19, N Engl J Med
Joyner, Senefeld, Klassen, Mills, Johnson et al., Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience, Infect Dis
Ko, Seok, Cho, Ha, Baek et al., Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antivir Ther
Korley, Durkalski-Mauldin, Yeatts, Schulman, Davenport et al., Early convalescent plasma for high-risk outpatients with COVID-19, N Engl J Med
Li, Zhang, Hu, Tong, Zheng et al., Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA
Libster, Marc, Wappner, Coviello, Bianchi et al., Early high-titer plasma therapy to prevent severe COVID-19 in older adults, N Engl J Med
Liu, Lin, Baine, Wajnberg, Gumprecht et al., Convalescent plasma treatment of severe COVID-19: a matched control study, Infect Dis
Maiztegui, Fernandez, De Damilano, Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome, Lancet Lond Engl
Medicine, Edoardo, Hospital, Internal and Emergency Medicine
Medicine, Hospital, Immunohematology and Transfusion Medicine
Medicine, Hospital, Ovada, 87 Internal medicine
Menichetti, Popoli, Puopolo, Alegiani, Tiseo et al., Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial, JAMA Netw Open
O'donnell, Grinsztejn, Cummings, Justman, Lamb et al., A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19, Infect Dis
Odutayo, Gryaznov, Copsey, Monk, Speich et al., Design, analysis and reporting of multi-arm trials and strategies to address multiple testing, Int J Epidemiol
Pathak, Convalescent plasma is ineffective for covid-19, BMJ
Perotti, Baldanti, Bruno, Fante, Seminari et al., Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial, Infect Dis
Ray, Paul, Bandopadhyay, 'rozario, Sarif et al., Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial, Infect Dis
Salazar, Christensen, Graviss, Nguyen, Castillo et al., Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Service, Hospital, Verduno, Italy. 92 Medical Emergency Division
Shen, Wang, Zhao, Yang, Li et al., Treatment of 5 critically ill patients with covid-19 with convalescent plasma, JAMA
Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med
Unit, Anthony, Arrigo, Hospital, Internal Medicine, Saints Anthony and Biagio and Cesare Arrigo Alessandria National Hospital
Vco, None
Zhou, Zhong, Guan, Treatment with convalescent plasma for influenza A (H5N1) infection, N Engl J Med
{ 'indexed': {'date-parts': [[2024, 8, 14]], 'date-time': '2024-08-14T20:31:19Z', 'timestamp': 1723667479385}, 'reference-count': 38, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 11, 22]], 'date-time': '2022-11-22T00:00:00Z', 'timestamp': 1669075200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 11, 22]], 'date-time': '2022-11-22T00:00:00Z', 'timestamp': 1669075200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>The efficacy of early treatment with convalescent plasma in patients ' 'with COVID-19 is debated. Nothing is known about the potential effect of other plasma ' 'components other than anti-SARS-CoV-2 antibodies.\n' '</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>To determine whether convalescent or standard plasma would improve ' 'outcomes for adults in early phase of Covid19 respiratory impairment we designed this ' 'randomized, three-arms, clinical trial (PLACO COVID) blinded on interventional arms that was ' 'conducted from June 2020 to August 2021. It was a multicentric trial at 19 Italian hospitals. ' 'We enrolled 180 hospitalized adult patients with COVID-19 pneumonia within 5\xa0days from the ' 'onset of respiratory distress. Patients were randomly assigned in a 1:1:1 ratio to standard ' 'of care (n\u2009=\u200960) or standard of care\u2009+\u2009three units of standard plasma ' '(n\u2009=\u200960) or standard of care\u2009+\u2009three units of high-titre convalescent ' 'plasma (n\u2009=\u200960) administered on days 1, 3, 5 after randomization. Primary outcome ' 'was 30-days mortality. Secondary outcomes were: incidence of mechanical ventilation or death ' 'at day 30, 6-month mortality, proportion of days with mechanical ventilation on total length ' 'of hospital stay, IgG anti-SARS-CoV-2 seroconversion, viral clearance from plasma and ' 'respiratory tract samples, and variations in Sequential Organ Failure Assessment score. The ' 'trial was analysed according to the intention-to-treat principle.\n' '</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>180 patients (133/180 [73.9%] males, mean age 66.6 years [IQR 57–73]) ' 'were enrolled a median of 8\xa0days from onset of symptoms. At enrollment, 88.9% of patients ' 'showed moderate/severe respiratory failure. 30-days mortality was 20% in Control arm, 23% in ' 'Convalescent (risk ratio [RR] 1.13; 95% confidence interval [CI], 0.61–2.13, P\u2009=\u2009' '0.694) and 25% in Standard plasma (RR 1.23; 95%CI, 0.63–2.37, P\u2009=\u20090.544). Time to ' 'viral clearance from respiratory tract was 21\xa0days for Convalescent, 28 for Standard ' 'plasma and 23 in Control arm but differences were not statistically significant. No ' 'differences for other secondary endpoints were seen in the three arms. Serious adverse events ' 'were reported in 1.7%, 3.3% and 5% of patients in Control, Standard and Convalescent plasma ' 'arms respectively.\n' '</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>Neither high-titer Convalescent nor Standard plasma improve outcomes ' 'of COVID-19 patients with acute respiratory failure.</jats:p>\n' ' <jats:p><jats:italic>Trial Registration</jats:italic> Clinicaltrials.gov ' 'Identifier: NCT04428021. First posted: 11/06/2020</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s12879-022-07716-5', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 11, 23]], 'date-time': '2022-11-23T09:29:15Z', 'timestamp': 1669195755000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients ' 'with respiratory impairment: short and long-term effects. A\xa0three-arm randomized controlled ' 'clinical trial', 'prefix': '10.1186', 'volume': '22', 'clinical-trial-number': [ { 'clinical-trial-number': 'nct04428021', 'registry': '10.18810/clinical-trials-gov'}], 'author': [ {'given': 'Paola Maria', 'family': 'Manzini', 'sequence': 'first', 'affiliation': []}, {'given': 'Giovannino', 'family': 'Ciccone', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Francesco Giuseppe', 'family': 'De Rosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rossana', 'family': 'Cavallo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valeria', 'family': 'Ghisetti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sergio', 'family': 'D’Antico', 'sequence': 'additional', 'affiliation': []}, {'given': 'Claudia', 'family': 'Galassi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabio', 'family': 'Saccona', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna', 'family': 'Castiglione', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nadia', 'family': 'Birocco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tiziana', 'family': 'Francisci', 'sequence': 'additional', 'affiliation': []}, {'given': 'Huijing', 'family': 'Hu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Clara', 'family': 'Pecoraro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Franca', 'family': 'Danielle', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luciana', 'family': 'Labanca', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna Maria', 'family': 'Bordiga', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco', 'family': 'Lorenzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giovanni', 'family': 'Camisasca', 'sequence': 'additional', 'affiliation': []}, {'given': 'Osvaldo', 'family': 'Giachino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mauro', 'family': 'Pagliarino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Piero', 'family': 'Ottone', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Ilvana Tiziana Donatella', 'family': 'Scuvera', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto', 'family': 'Guaschino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto', 'family': 'Freilone', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pierluigi', 'family': 'Berti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabrizia', 'family': 'Pittaluga', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria', 'family': 'Avolio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cristina', 'family': 'Costa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Samuele', 'family': 'Raso', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aurora', 'family': 'Nucci', 'sequence': 'additional', 'affiliation': []}, {'given': 'Massimo', 'family': 'Milan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandra', 'family': 'Baffa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandra', 'family': 'Russo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antonella', 'family': 'Tornello', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Maddalena', 'sequence': 'additional', 'affiliation': []}, {'given': 'Grazia', 'family': 'Delios', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabio Paolo', 'family': 'Marletto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna Grazia', 'family': 'De Micheli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessio', 'family': 'Mattei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stefano', 'family': 'Baldassano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesca', 'family': 'Canta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Luisa', 'family': 'Russo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniele', 'family': 'Bergamo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesco', 'family': 'Vitale', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco Maria', 'family': 'Liccardi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandra', 'family': 'Chinaglia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrea', 'family': 'Calcagno', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marcella', 'family': 'Converso', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chiara', 'family': 'Aldieri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valentina', 'family': 'Libanore', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ilaria', 'family': 'Blangetti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valentina', 'family': 'Benedetti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Barbara', 'family': 'Mitola', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gitana', 'family': 'Scozzari', 'sequence': 'additional', 'affiliation': []}, {'name': 'the PLACO COVID Study Group', 'sequence': 'additional', 'affiliation': []}, {'given': 'Franco', 'family': 'Castagno', 'sequence': 'additional', 'affiliation': []}, {'given': 'Adriano', 'family': 'Valfrè', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gabriella', 'family': 'Rizzioli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Teresa', 'family': 'D’Amato', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cristina', 'family': 'Crocillà', 'sequence': 'additional', 'affiliation': []}, {'given': 'Silvana', 'family': 'Naselli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valentino', 'family': 'Granero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Grazia', 'family': 'Cornagliotto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Graziella', 'family': 'Lucania', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cristiana', 'family': 'Scaglia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesca', 'family': 'Ferro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carmela', 'family': 'Solimine', 'sequence': 'additional', 'affiliation': []}, {'given': 'Monica', 'family': 'Ricotti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cristina', 'family': 'Gilestro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Remigio', 'family': 'Roncato', 'sequence': 'additional', 'affiliation': []}, {'given': 'Angela', 'family': 'Palladino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniela', 'family': 'Ongaro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giulia Anna', 'family': 'Poggio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chiara', 'family': 'Chiappero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Simone Mornese', 'family': 'Pinna', 'sequence': 'additional', 'affiliation': []}, {'given': 'Silvia', 'family': 'Scabini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Federico', 'family': 'Vischia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Grazia', 'family': 'Gregoretti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enrico', 'family': 'Lupia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luca', 'family': 'Brazzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlo', 'family': 'Albera', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luca', 'family': 'Scaglione', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valter', 'family': 'Gallo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Claudio', 'family': 'Norbiato', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto', 'family': 'Albiani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno Lucio', 'family': 'Sini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrea', 'family': 'Fassiola', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandro', 'family': 'Locatelli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giovanni', 'family': 'Di Perri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mauro', 'family': 'Navarra', 'sequence': 'additional', 'affiliation': []}, {'given': 'Isabella', 'family': 'Gardini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aurora', 'family': 'Ciardiello', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rita', 'family': 'La Grotta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna', 'family': 'De Rosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paola', 'family': 'Pasquino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gilberto', 'family': 'Fiore', 'sequence': 'additional', 'affiliation': []}, {'given': 'Orietta', 'family': 'Franza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paola', 'family': 'Artoni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stefano', 'family': 'Meinardi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liliana', 'family': 'Calosso', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paola', 'family': 'Molino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Grazia', 'family': 'Veglio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tiziana', 'family': 'Beltramo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Odetta', 'family': 'Camerini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karol', 'family': 'Giancaspero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Franca', 'family': 'Napoli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alberto', 'family': 'Perboni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emanuela', 'family': 'Messa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabrizio', 'family': 'Buffolo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fiammetta', 'family': 'Pagnozzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stefania', 'family': 'Bertone', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lorenzo', 'family': 'Lutri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Umberto', 'family': 'Gravante', 'sequence': 'additional', 'affiliation': []}, {'given': 'Petros', 'family': 'Sacchetti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandra', 'family': 'Pavan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enzo', 'family': 'Castenetto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco', 'family': 'Novelli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco', 'family': 'Tucciarone', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrizia', 'family': 'Ocello', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giulia', 'family': 'Guido', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chiara', 'family': 'Frascaroli', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Daniela Maria Luisa', 'family': 'Vivenza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesca', 'family': 'Patti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Lorenzelli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guido', 'family': 'Balduzzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Deborah', 'family': 'Ratti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Mazzucco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valeria', 'family': 'Balbo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesca', 'family': 'Pollis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sabrina', 'family': 'Leoncino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chiara', 'family': 'Lupo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniele', 'family': 'Romano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Silvia', 'family': 'Ziccardi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Melania', 'family': 'Marmifero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guido', 'family': 'Chichino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mario', 'family': 'Salio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giuseppe', 'family': 'Aiosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Riccardo', 'family': 'Boverio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ilaria', 'family': 'Avonto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sara', 'family': 'Ghiotto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Riccardo', 'family': 'Balbo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincenza', 'family': 'Nico', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chiara', 'family': 'Aguzzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Chiara', 'family': 'Pellegrino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maristella', 'family': 'Prucca', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lucia Assunta', 'family': 'Longa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Perotti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Federica', 'family': 'Piovano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luca', 'family': 'Ambrogio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco', 'family': 'Formica', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elisa', 'family': 'Monge', 'sequence': 'additional', 'affiliation': []}, {'given': 'Flavia', 'family': 'Arena', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicoletta', 'family': 'Barzaghi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Silvia', 'family': 'Tavera', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mariaelisa', 'family': 'Canepari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Guido', 'family': 'Strani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fulvio', 'family': 'Pomero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Grazia', 'family': 'Cianci', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mariella', 'family': 'Gianarda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Leonardo', 'family': 'Ruscitto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniel', 'family': 'De Martino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sandro', 'family': 'Macchi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michele', 'family': 'Montagnana', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vladimiro', 'family': 'Grandinetti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Silvia', 'family': 'Magnani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elisabetta', 'family': 'Radin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valentina', 'family': 'Pellu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Monica', 'family': 'Meucci', 'sequence': 'additional', 'affiliation': []}, {'given': 'Erika', 'family': 'Noè', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paola', 'family': 'Torti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luca', 'family': 'Montagnani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giulio', 'family': 'Doveri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gabriella', 'family': 'Giustetto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Costantino', 'family': 'Avdis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco', 'family': 'Prina', 'sequence': 'additional', 'affiliation': []}, {'given': 'Franco', 'family': 'Eliantonio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francesco', 'family': 'Lemut', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giuseppe', 'family': 'Semino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Palmina', 'family': 'Spidalieri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Domenico', 'family': 'Vallino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto', 'family': 'Prota', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gabriella', 'family': 'Buono', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincenzo', 'family': 'Segala', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Grazia', 'family': 'Milia', 'sequence': 'additional', 'affiliation': []}, {'given': 'Franco', 'family': 'Aprà', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sergio', 'family': 'Livigni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emilpaolo', 'family': 'Manno', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giuseppe', 'family': 'Caula', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emanuela', 'family': 'Vitali', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicola', 'family': 'Liuzzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mauro', 'family': 'Pastorelli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pietro', 'family': 'Caironi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Federica', 'family': 'Gamna', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno', 'family': 'Scapino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lorenzo', 'family': 'Gurioli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emanuele', 'family': 'Magro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giuseppe', 'family': 'Roberti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gian Mario', 'family': 'Santamaria', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antonella', 'family': 'Daffonchio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paola', 'family': 'Varese', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gianfranco', 'family': 'Ghiazza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Margherita', 'family': 'Girino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carolina', 'family': 'Pelazza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fabrizio', 'family': 'Racca', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mirco', 'family': 'Grillo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valerio', 'family': 'Del Bono', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giorgio', 'family': 'Gianotto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enzo', 'family': 'Aluffi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enrico', 'family': 'Ravera', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 11, 22]]}, 'reference': [ { 'key': '7716_CR1', 'doi-asserted-by': 'publisher', 'first-page': '1216', 'DOI': '10.1016/S0140-6736(79)92335-3', 'volume': '2', 'author': 'JI Maiztegui', 'year': '1979', 'unstructured': 'Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in ' 'treatment of Argentine haemorrhagic fever and association between ' 'treatment and a late neurological syndrome. Lancet Lond Engl. ' '1979;2:1216–7.', 'journal-title': 'Lancet Lond Engl'}, { 'key': '7716_CR2', 'doi-asserted-by': 'publisher', 'first-page': '617', 'DOI': '10.3851/IMP3243', 'volume': '23', 'author': 'J-H Ko', 'year': '2018', 'unstructured': 'Ko J-H, Seok H, Cho SY, Eun Ha Y, Baek JY, Kim SH, et al. Challenges of ' 'convalescent plasma infusion therapy in Middle East respiratory ' 'coronavirus infection: a single centre experience. Antivir Ther. ' '2018;23:617–22.', 'journal-title': 'Antivir Ther'}, { 'key': '7716_CR3', 'doi-asserted-by': 'publisher', 'first-page': '44', 'DOI': '10.1007/s10096-004-1271-9', 'volume': '24', 'author': 'Y Cheng', 'year': '2005', 'unstructured': 'Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of ' 'convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin ' 'Microbiol Infect Dis. 2005;24:44–6.', 'journal-title': 'Eur J Clin Microbiol Infect Dis'}, { 'key': '7716_CR4', 'doi-asserted-by': 'publisher', 'first-page': '447', 'DOI': '10.1093/cid/ciq106', 'volume': '52', 'author': 'IF Hung', 'year': '2011', 'unstructured': 'Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. Convalescent ' 'plasma treatment reduced mortality in patients with severe pandemic ' 'influenza A (H1N1) 2009 virus infection. Clin Infect Dis. ' '2011;52:447–56.', 'journal-title': 'Clin Infect Dis'}, { 'key': '7716_CR5', 'doi-asserted-by': 'publisher', 'first-page': '1450', 'DOI': '10.1056/NEJMc070359', 'volume': '357', 'author': 'B Zhou', 'year': '2007', 'unstructured': 'Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for ' 'influenza A (H5N1) infection. N Engl J Med. 2007;357:1450–1.', 'journal-title': 'N Engl J Med'}, { 'key': '7716_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1582', 'DOI': '10.1001/jama.2020.4783', 'volume': '323', 'author': 'C Shen', 'year': '2020', 'unstructured': 'Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 ' 'critically ill patients with covid-19 with convalescent plasma. JAMA. ' '2020;323:1582–9.', 'journal-title': 'JAMA'}, { 'key': '7716_CR7', 'doi-asserted-by': 'publisher', 'first-page': '9490', 'DOI': '10.1073/pnas.2004168117', 'volume': '117', 'author': 'K Duan', 'year': '2020', 'unstructured': 'Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of ' 'convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad ' 'Sci. 2020;117:9490–6.', 'journal-title': 'Proc Natl Acad Sci'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et ' 'al. Effect of convalescent plasma on mortality among hospitalized ' 'patients with COVID-19: initial three-month experience. Infect Dis ' '(except HIV/AIDS); 2020.', 'key': '7716_CR8', 'DOI': '10.1101/2020.08.12.20169359'}, { 'key': '7716_CR9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.transci.2020.102875', 'volume': '59', 'author': 'H Abolghasemi', 'year': '2020', 'unstructured': 'Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki ' 'Moghaddam F, Imanizadeh S, et al. Clinical efficacy of convalescent ' 'plasma for treatment of COVID-19 infections: results of a multicenter ' 'clinical study. Transfus Apher Sci. 2020;59.', 'journal-title': 'Transfus Apher Sci'}, { 'key': '7716_CR10', 'doi-asserted-by': 'publisher', 'first-page': '759', 'DOI': '10.1182/blood.2020006964', 'volume': '136', 'author': 'L Hegerova', 'year': '2020', 'unstructured': 'Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. ' 'Use of convalescent plasma in hospitalized patients with COVID-19: case ' 'series. Blood. 2020;136:759–62.', 'journal-title': 'Blood'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, et ' 'al. Mortality reduction in 46 severe COVID-19 patients treated with ' 'hyperimmune plasma. A proof of concept single arm multicenter ' 'interventional trial. Infect Dis (except HIV/AIDS); 2020.', 'key': '7716_CR11', 'DOI': '10.1101/2020.05.26.20113373'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. ' 'Convalescent plasma treatment of severe COVID-19: a matched control ' 'study. Infect Dis (except HIV/AIDS); 2020.', 'key': '7716_CR12', 'DOI': '10.1101/2020.05.20.20102236'}, { 'key': '7716_CR13', 'doi-asserted-by': 'publisher', 'first-page': '2290', 'DOI': '10.1016/j.ajpath.2020.08.001', 'volume': '190', 'author': 'E Salazar', 'year': '2020', 'unstructured': 'Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et ' 'al. Treatment of coronavirus disease 2019 patients with convalescent ' 'plasma reveals a signal of significantly decreased mortality. Am J ' 'Pathol. 2020;190:2290–303.', 'journal-title': 'Am J Pathol'}, { 'key': '7716_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1170', 'DOI': '10.1186/s12879-021-06829-7', 'volume': '21', 'author': 'C Axfors', 'year': '2021', 'unstructured': 'Axfors C, Janiaud P, Schmitt AM, van’t Hooft J, Smith ER, Haber NA, et ' 'al. Association between convalescent plasma treatment and mortality in ' 'COVID-19: a collaborative systematic review and meta-analysis of ' 'randomized clinical trials. BMC Infect Dis. 2021;21:1170.', 'journal-title': 'BMC Infect Dis'}, { 'key': '7716_CR15', 'doi-asserted-by': 'publisher', 'first-page': '968', 'DOI': '10.1093/ije/dyaa026', 'volume': '49', 'author': 'A Odutayo', 'year': '2020', 'unstructured': 'Odutayo A, Gryaznov D, Copsey B, Monk P, Speich B, Roberts C, et al. ' 'Design, analysis and reporting of multi-arm trials and strategies to ' 'address multiple testing. Int J Epidemiol. 2020;49:968–78.', 'journal-title': 'Int J Epidemiol'}, { 'key': '7716_CR16', 'doi-asserted-by': 'publisher', 'first-page': '460', 'DOI': '10.1001/jama.2020.10044', 'volume': '324', 'author': 'L Li', 'year': '2020', 'unstructured': 'Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of ' 'convalescent plasma therapy on time to clinical improvement in patients ' 'with severe and life-threatening COVID-19: a randomized clinical trial. ' 'JAMA. 2020;324:460.', 'journal-title': 'JAMA'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Gharbharan A, Jordans CCE, Geurtsvankessel C, den Hollander JG, Karim F, ' 'Mollema FPN, et al. Convalescent Plasma for COVID-19. A randomized ' 'clinical trial. Infect Dis (except HIV/AIDS); 2020.', 'key': '7716_CR17', 'DOI': '10.1101/2020.07.01.20139857'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. ' 'Convalescent plasma in the management of moderate covid-19 in adults in ' 'India: open label phase II multicentre randomised controlled trial ' '(PLACID Trial). BMJ. 2020;m3939.', 'key': '7716_CR18', 'DOI': '10.1136/bmj.m3939'}, { 'key': '7716_CR19', 'doi-asserted-by': 'publisher', 'first-page': '619', 'DOI': '10.1056/NEJMoa2031304', 'volume': '384', 'author': 'VA Simonovich', 'year': '2021', 'unstructured': 'Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, ' 'Vázquez C, et al. A randomized trial of convalescent plasma in COVID-19 ' 'severe pneumonia. N Engl J Med. 2021;384:619–29.', 'journal-title': 'N Engl J Med'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Bajpai M, Kumar S, Maheshwari A, Chhabra K, kale P, Gupta A, et al. ' 'Efficacy of convalescent plasma therapy compared to fresh frozen plasma ' 'in severely ill COVID-19 patients: a pilot randomized controlled trial. ' 'Infect Dis (except HIV/AIDS); 2020.', 'key': '7716_CR20', 'DOI': '10.1101/2020.10.25.20219337'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab ' 'AH, et al. Randomized controlled trial of convalescent plasma therapy ' 'against standard therapy in patients with severe COVID-19 disease. ' 'Infect Dis (except HIV/AIDS); 2020.', 'key': '7716_CR21', 'DOI': '10.1101/2020.11.02.20224303'}, { 'key': '7716_CR22', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pmed.1003415', 'volume': '18', 'author': 'ME Balcells', 'year': '2021', 'unstructured': 'Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, ' 'Ferrés M, et al. Early versus deferred anti-SARS-CoV-2 convalescent ' 'plasma in patients admitted for COVID-19: a randomized phase II clinical ' 'trial. PLoS Med. 2021;18.', 'journal-title': 'PLoS Med'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Ray Y, Paul SR, Bandopadhyay P, D’Rozario R, Sarif J, Lahiri A, et al. ' 'Clinical and immunological benefits of convalescent plasma therapy in ' 'severe COVID-19: insights from a single center open label randomised ' 'control trial. Infect Dis (except HIV/AIDS); 2020.', 'key': '7716_CR23', 'DOI': '10.1101/2020.11.25.20237883'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Avendaño-Solà C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, de ' 'Molina RM, Torres F, et al. Convalescent plasma for COVID-19: a ' 'multicenter, randomized clinical trial. Infect Dis (except HIV/AIDS); ' '2020.', 'key': '7716_CR24', 'DOI': '10.1101/2020.08.26.20182444'}, { 'key': '7716_CR25', 'doi-asserted-by': 'publisher', 'first-page': '610', 'DOI': '10.1056/NEJMoa2033700', 'volume': '384', 'author': 'R Libster', 'year': '2021', 'unstructured': 'Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et ' 'al. Early high-titer plasma therapy to prevent severe COVID-19 in older ' 'adults. N Engl J Med. 2021;384:610–8.', 'journal-title': 'N Engl J Med'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'O’Donnell MR, Grinsztejn B, Cummings MJ, Justman J, Lamb MR, Eckhardt ' 'CM, et al. A randomized, double-blind, controlled trial of convalescent ' 'plasma in adults with severe COVID-19. Infect Dis (except HIV/AIDS); ' '2021.', 'key': '7716_CR26', 'DOI': '10.1101/2021.03.12.21253373'}, { 'key': '7716_CR27', 'doi-asserted-by': 'publisher', 'first-page': '2049', 'DOI': '10.1016/S0140-6736(21)00897-7', 'volume': '397', 'author': 'RECOVERY Collaborative Group', 'year': '2021', 'unstructured': 'RECOVERY Collaborative Group. Convalescent plasma in patients admitted ' 'to hospital with COVID-19 (RECOVERY): a randomised controlled, ' 'open-label, platform trial. Lancet Lond Engl. 2021;397:2049–59.', 'journal-title': 'Lancet Lond Engl'}, { 'key': '7716_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1015', 'DOI': '10.1056/NEJMoa2031893', 'volume': '384', 'author': 'MJ Joyner', 'year': '2021', 'unstructured': 'Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et ' 'al. Convalescent plasma antibody levels and the risk of death from ' 'COVID-19. N Engl J Med. 2021;384:1015–27.', 'journal-title': 'N Engl J Med'}, { 'key': '7716_CR29', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-021-01488-2', 'author': 'P Bégin', 'year': '2021', 'unstructured': 'Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. ' 'Convalescent plasma for hospitalized patients with COVID-19: an ' 'open-label, randomized controlled trial. Nat Med. 2021. ' 'https://doi.org/10.1038/s41591-021-01488-2.', 'journal-title': 'Nat Med'}, { 'key': '7716_CR30', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2021.36246', 'volume': '4', 'author': 'F Menichetti', 'year': '2021', 'unstructured': 'Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni ' 'A, et al. Effect of high-titer convalescent plasma on progression to ' 'severe respiratory failure or death in hospitalized patients with ' 'COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open. 2021;4.', 'journal-title': 'JAMA Netw Open'}, { 'key': '7716_CR31', 'doi-asserted-by': 'publisher', 'first-page': '1951', 'DOI': '10.1056/NEJMoa2103784', 'volume': '385', 'author': 'FK Korley', 'year': '2021', 'unstructured': 'Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, ' 'Dumont LJ, et al. Early convalescent plasma for high-risk outpatients ' 'with COVID-19. N Engl J Med. 2021;385:1951.', 'journal-title': 'N Engl J Med'}, { 'key': '7716_CR32', 'doi-asserted-by': 'publisher', 'first-page': '1937', 'DOI': '10.1093/cid/ciaa449', 'volume': '71', 'author': 'X Chen', 'year': '2020', 'unstructured': 'Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum ' 'severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is ' 'closely correlated with drastically elevated interleukin 6 level in ' 'critically ill patients with coronavirus disease 2019. Clin Infect Dis. ' '2020;71:1937–42.', 'journal-title': 'Clin Infect Dis'}, { 'key': '7716_CR33', 'doi-asserted-by': 'publisher', 'first-page': '469', 'DOI': '10.1080/22221751.2020.1732837', 'volume': '9', 'author': 'W Chen', 'year': '2020', 'unstructured': 'Chen W, Lan Y, Yuan X, Deng X, Li Y, Cai X, et al. Detectable 2019-nCoV ' 'viral RNA in blood is a strong indicator for the further clinical ' 'severity. Emerg Microbes Infect. 2020;9:469–73.', 'journal-title': 'Emerg Microbes Infect'}, { 'key': '7716_CR34', 'doi-asserted-by': 'publisher', 'first-page': 'e291', 'DOI': '10.1093/cid/ciaa1054', 'volume': '72', 'author': 'CA Hogan', 'year': '2021', 'unstructured': 'Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, et al. ' 'High frequency of SARS-CoV-2 RNAemia and association with severe ' 'disease. Clin Infect Dis. 2021;72:e291–5.', 'journal-title': 'Clin Infect Dis'}, { 'key': '7716_CR35', 'doi-asserted-by': 'publisher', 'first-page': 'e2995', 'DOI': '10.1093/cid/ciaa1285', 'volume': '73', 'author': 'K Hagman', 'year': '2020', 'unstructured': 'Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner ' 'J, et al. Severe acute respiratory syndrome coronavirus 2 RNA in serum ' 'as predictor of severe outcome in coronavirus disease 2019: a ' 'retrospective cohort study. Clin Infect Dis. 2020;73:e2995.', 'journal-title': 'Clin Infect Dis'}, { 'key': '7716_CR36', 'doi-asserted-by': 'publisher', 'first-page': '1045', 'DOI': '10.3390/v12091045', 'volume': '12', 'author': 'KA Eberhardt', 'year': '2020', 'unstructured': 'Eberhardt KA, Meyer-Schwickerath C, Heger E, Knops E, Lehmann C, ' 'Rybniker J, et al. RNAemia corresponds to disease severity and antibody ' 'response in hospitalized COVID-19 patients. Viruses. 2020;12:1045.', 'journal-title': 'Viruses'}, { 'key': '7716_CR37', 'doi-asserted-by': 'publisher', 'first-page': '1888', 'DOI': '10.1016/j.mayocp.2020.06.028', 'volume': '95', 'author': 'MJ Joyner', 'year': '2020', 'unstructured': 'Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. ' 'Safety update: COVID-19 convalescent plasma in 20,000 hospitalized ' 'patients. Mayo Clin Proc. 2020;95:1888–97.', 'journal-title': 'Mayo Clin Proc'}, { 'doi-asserted-by': 'crossref', 'unstructured': 'Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ. ' '2020;m4072.', 'key': '7716_CR38', 'DOI': '10.1136/bmj.m4072'}], 'container-title': 'BMC Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-022-07716-5.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12879-022-07716-5/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-022-07716-5.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 11, 23]], 'date-time': '2022-11-23T09:29:31Z', 'timestamp': 1669195771000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07716-5'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 11, 22]]}, 'references-count': 38, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['7716'], 'URL': 'http://dx.doi.org/10.1186/s12879-022-07716-5', 'relation': {}, 'ISSN': ['1471-2334'], 'subject': [], 'container-title-short': 'BMC Infect Dis', 'published': {'date-parts': [[2022, 11, 22]]}, 'assertion': [ { 'value': '21 February 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '30 August 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '22 November 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The trial protocol was approved by the Ethical Committee of the coordinating ' 'center: Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza ' 'di Torino—A.O. Ordine Mauriziano di Torino—A.S.L. Città di Torino and then by ' 'all ethical Committee at each participating center and was conducted following ' 'the principles stated in the declaration of Helsinki and the Good Clinical ' 'Practice Guidelines. A written informed consent was obtained from all subjects ' '(donors and patients) and/or their legal guardian(s) before enrollment. The ' 'informed consent is available in the\xa0Study Protocol\xa0available in the ' 'online version—see Supplementary Information).', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare that they have no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '879'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit